	eduction Act of 1995, no pers	ons are required to respond to a col	Patent and Tra lection of info	(Substitute) PTO/SB/21 (894) Approved to use through 07/31/2006. OMB 0651-003 ademark Office; U.S. DEPARTMENT OF COMMERC amation unless it displays a valid OMB control number
DEMERAL OF TRANS		Application Number	10/518,2	214
TRANSMITTAL FORM			Filing Date December 16, 2004	
		First Named Inventor	Reddy Bandi Partilasarauni, et ai	
·		Art Unit Examiner Name		
(to be used for all corresp	ondence after initial filing)			
Total Number of Pages in This Submission 269		Attorney Docket Number	H1089/20024	
	EN	CLOSURES (Check all	that apply)	
Fee Transmittal Fo		Drawing(s)		After Allowance Communication to TO
Fee Attach	ed	Licensing-related Papers		Appeal Communication to Board of Appeals and Interferences
Amendment/Reply		Petition		Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
After Final		Petition to Convert to a Provisional Application		Proprietary Information
		Power of Attorney, Revocation Change of Correspondence Address		Status Letter
Affidavits/declaration(s)		Terminal Disclaimer		Other Enclosure(s) (please Identify
Extension of Time Request				PTO FORM 1449 AND CITED
Express Abandonment Request		Request for Refund		REFERENCES
Information Disclosure Statement		CD, Number of CD(s)		RETURN RECEIPT POSTCARD
		Landscape Table on C	D	
Certified Copy of Document(s)	Priority Re	marks		
Reply to Missing I Incomplete Applic Reply to M under 37 0	ation lissing Parts CFR 1.52 or 1.53			
	ens	ure consideration of this sub	mission.	75 as necessary to effect entry and/or
		E OF APPLICANT, ATTO		
Firm Name Caesa	ır, Rivise, Bernstein, C	ohen & Pokotilow, Ltd., Cus	tomer No.	03000
Signature				
Printed name Robert S. Silver				
Date 2/	, /2005		Reg. No.	35,681
	CERT	IFICATE OF TRANSMIS	SION/MA	ILING
I hereby certify that this c	orrespondence is being f	acsimile transmitted to the USP	TO or depos	sited with the United States Postal Service wit P.O. Box 1450, Alexandria, VA 22313-1450 or

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Robert S. Silver

Typed or printed name

2005 المحتول

Date



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE PATENT EXAMINING OPERATION

Applicant(s): Reddy Bandi Parthasaradhi, et al

Serial No: 10/518,214

Group Art Unit:

Filed: December 16, 2004

Examiner:

Att. Docket No.: H1089/20024

Confirmation No.:

For: A

ARIPIPRAZOLE CRYSTALLINE FORMS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom. No representation is made that the reference(s) is/are prior art with respect to this application.

This Information Disclosure Statement is being filed within three months of the filing date of a national application other than a CPA under 37 CFR § 1.53(d), within three months of the date of entry of the national stage as set forth in 37 CFR § 1.491 in an international application, before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of an RCE under 37 CFR § 1.114. No certification or fee is required. 37 CFR § 1.97(b).

Application No. 10/518,214

Regarding JP Unexamined Patent Publication No. 191256, Applicants believe that this publication is equivalent to the disclosure of U. S. Patent No. 5,006,528 (enclosed), which provides the English translation of JP 19125, as required.

Respectfully submitted,

CAESAR, RIVISE, BERNSTEIN COHEN & POKOTILOW, LTD.

February 25, 2005

Please charge or credit our Account No. 03-0075 as necessary to effect entry and/or ensure consideration of this submission.

Robert S. Silver
Registration/No. 35,681
Customer/No. 03000
(215) 567-2010

Attorneys for Applicant(s)

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

October 1996, CR 119, pp. 937-940

Korea Symposium on Separation Technology. The Korean Institute of Chemical Engineers,